High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
We measured soluble CD44 (sCD44) by enzyme-linked immunosorbent assay in 216 patients with non-Hodgkin's lymphoma (NHL). The sCD44 level was significantly elevated in patients with NHL. A sCD44 level of > or =500 ng/ml showed a significantly decreased overall survival (OS) rate and progression free survival (PFS) rate. In the high-intermediate+high risk group (international prognostic index (IPI)), both the OS rate and the PFS rate were significantly decreased when the sCD44 level was > or =1000 ng/ml. Moreover, the results of a multivariate analysis showed that the five IPI prognostic factors and the sCD44 level were independent prognostic factors, thus suggesting that sCD44 levels could be a useful prognostic marker for aggressive lymphoma
Niitsu
Nozomi
N
Department of Hematology and Internal Medicine, Internal Medicin IV, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara-Shi, Kanagawa 228-8555, Japan. nniitsu@med.kitasato-u.ac.jp
Iijima
Kimiko
K
D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000097:blood*; D016393:Lymphoma, B-Cell / Q000097:blood / Q000401:mortality / Q000473:pathology; D018442:Lymphoma, B-Cell, Marginal Zone / Q000097:blood / Q000401:mortality / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000145:classification / Q000401:mortality* / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000097:blood / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D012016:Reference Values; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
D015703:Antigens, CD; D014408:Biomarkers, Tumor; D018960:Hyaluronan Receptors